抗体薬物複合体（ADC）の世界市場レポート 2024

抗体薬物複合体（ADC）の市場規模は、今後数年間で急激に成長すると予想されています。 2028年には23.4%の年間複合成長率（CAGR）で248億米ドルに成長すると予想されます。抗体薬物複合体（ADC）市場の予測期間における予想される成長は、次世代ADCの開発、その使用適応症の拡大、がん治療における個別化医療への注目の高まり、投資の増加などの要因に起因すると考えられます。予測期間中に予想される主な動向には、コンジュゲーション技術の進歩、ADC開発に影響を与える腫瘍生物学の理解の向上、この分野での継続的な技術進歩、ADCの治療用途の拡大、ドラッグデリバリーの強化のための高度なコンジュゲーション技術の継続的な進化が含まれます。

世界の抗体薬物複合体（ADC）市場は、世界中でがんの発生率が増加していることにより大幅な成長を遂げています。肥満、喫煙、飲酒、不適切な食習慣など、ほとんどのがんの主な原因が増加傾向に寄与しています。Cancer Research UKは大幅な増加を予測し、2040年までに年間2,750万人の新たながん症例が発生すると推定しています。このがん発生率の急増により、抗体薬物複合体（ADC）の需要が高まり、市場の成長が促進されると予想されます。

抗体薬物複合体（ADC）市場の上昇軌道は、臨床試験研究の数の増加によってさらに加速されています。新しい治療法や介入をテストするために不可欠な臨床試験は、疾患管理において重要な役割を果たします。抗体薬物複合体（ADC）は、抗がん剤の重要なカテゴリーとして、血液関連のがんや固形腫瘍を治療するために数多くの臨床試験が行われています。注目すべきことに、世界中で登録臨床試験が大幅に増加しており、2023年5月にThe Xtalksが報じたところによると、ClinicalTrials.govには452,604件が掲載されています。この上昇傾向は臨床研究の重要性が高まっていることを示しており、抗体医薬品の拡大に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 市場促進要因・市場抑制要因
  • 市場促進要因
  • 市場抑制要因
• 市場規模と成長実績、2018～2023年
• 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の抗体薬物複合体（ADC）市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• モノクローナル抗体
• リンカー
• 薬物/毒素
• その他
• 世界の抗体薬物複合体（ADC）市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• アドセトリス
• カドサイラ
• その他
• 世界の抗体薬物複合体（ADC）市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• イムノゲン
• Seattle Genetics
• Immunomedics
• その他
• 世界の抗体薬物複合体（ADC）市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 血液がん
• 乳がん
• 卵巣がん
• 肺がん
• 脳腫瘍
• その他
• 世界の抗体薬物複合体（ADC）市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• その他

第7章 地域および国の分析

• 世界の抗体薬物複合体（ADC）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の抗体薬物複合体（ADC）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗体薬物複合体（ADC）市場の競合情勢
• 抗体薬物複合体（ADC）市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • AstraZeneca plc

第31章 その他の大手および革新的な企業

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Millennium Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company Limited
• Sorrento Therapeutics Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Zydus Lifesciences Limited
• Seagen Inc.
• Seagen Inc.
• Progenics Pharmaceuticals Inc.
• Synthon BV
• Genentech Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Antibody-drug conjugates (ADCs) are medications specifically designed to deliver chemotherapy to cancer cells. They consist of a cytotoxic drug linked to a monoclonal antibody, which binds to a specific target expressed on cancer cells. Upon binding to the target, the ADC releases a cytotoxic chemical into the cancer cell, aiming to destroy it.

The main components of antibody-drug conjugates include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are generated by cloning a single white blood cell, and each subsequent antibody is derived from a single parent cell. Some examples of ADC products include Adcetris, Kadcyla, and others. Various technologies, such as immunogen technology, Seattle Genetics technology, immunomedics technology, among others, are involved in the development of antibody-drug conjugates. These therapies find applications in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others, and are implemented in hospitals, clinics, and other healthcare settings.

The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $8.78 billion in 2023 to $10.7 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%. The growth observed during the historical period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the increasing prevalence of cancer, successful clinical outcomes leading to regulatory approvals, strategic collaborations between pharmaceutical companies, a rise in investment in research and development (R&D) initiatives, and the implementation of market expansion strategies.

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The anticipated growth in the forecast period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the development of next-generation ADCs, expanding indications for their use, an increasing focus on personalized medicine in cancer treatment, rising investment in precision medicine approaches, and a growing awareness of healthcare options. Major trends expected in the forecast period include advancements in conjugation technologies, an improved understanding of tumor biology influencing ADC development, ongoing technological advancements in the field, expanding therapeutic applications for ADCs, and the continuous evolution of advanced conjugation technologies for enhanced drug delivery.

The global antibody-drug conjugates market is witnessing significant growth driven by the increasing incidence of cancer worldwide. Primary causes of most cancers, including obesity, smoking, alcohol consumption, and poor dietary habits, contribute to a rising trend. Cancer Research UK projects a substantial increase, estimating 27.5 million new cancer cases annually by 2040. This surge in cancer incidences is expected to boost the demand for antibody-drug conjugates, thereby propelling market growth.

The upward trajectory of the antibody-drug conjugates market is further fueled by a growing number of clinical trial studies. Clinical trials, essential for testing new treatments and interventions, play a crucial role in disease management. Antibody-drug conjugates, as a significant category of anti-cancer medications, are undergoing numerous clinical trials for treating blood-related cancers and solid tumors. Notably, there has been a substantial increase in registered clinical trials worldwide, with 452,604 listed on ClinicalTrials.gov, as reported by The Xtalks in May 2023. This uptrend indicates the rising prominence of clinical studies, contributing to the expansion of the antibody-drug conjugates market.

Challenges in the manufacturing process of antibody-drug conjugates act as a restraint on market growth. ADC manufacturing facilities require substantial capital investment and specialized training for operators. The complexity of ADC process development, involving additional steps not present in conventional monoclonal antibody manufacturing, poses operational difficulties. Challenges include optimizing antibody-drug conjugation reactions and subsequent drug substance purification, along with the need for aseptic environments and protection of personnel from highly toxic drug compounds.

Manufacturers of antibody-drug conjugates are subject to monitoring by regulatory bodies, such as the Food and Drug Administration (FDA) in the USA. Although there is no specific regulatory guidance for ADC development, the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. Regulatory oversight focuses on aspects such as the manufacturing of the antibody component, control strategy for antibody intermediate, drug substance, and drug product. Small molecule review groups at the FDA play a key role in evaluating payload and linker adequacy, conjugation reactions, and aspects of the control strategy.

Manufacturers are increasingly engaging in collaborations and partnerships to share technology, resources, and product knowledge. An example is the collaboration between Sanofi, a French multinational pharmaceutical company, and Seagen Inc., a US biotechnology company, announced in March 2022. This collaboration aims to develop and market up to three cancer targets for antibody-drug conjugates, leveraging Sanofi's exclusive monoclonal antibody technology and Seagen's exclusive ADC technology. Such collaborations enhance synergies, fostering the creation of candidate medications to offer new hope to cancer patients.

Major companies in the antibody-drug conjugates market are introducing innovative breakthrough conjugates such as Ujvira to offer affordable new therapies. Ujvira, launched by Zydus Cadila in May 2021, is the world's first biosimilar antibody-drug conjugate of trastuzumab emtansine. This breakthrough treatment targets breast and stomach cancer by inhibiting the human epidermal growth factor receptor protein (HER2). Administered by qualified medical professionals, Ujvira represents a significant advancement in cancer therapy.

Major companies operating in the antibody drug conjugates market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Biogen Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Progenics Pharmaceuticals Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Fredax, Eisai Co. Ltd., Merck KGaA, Bracco S.p.A.

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2023. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Drug Conjugates Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibody drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Monoclonal Antibodies; Linker; Drug/Toxin; Other Types
• 2) By Product: Adcertis; Kadcyla; Other Products
• 3) By Technology: Immunogen Technology; Seattle Genetics Technology; Immunomedics Technology; Other Technology
• 4) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
• 5) By End User: Hospital; Clinics; Other End Users
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antibody Drug Conjugates Market Characteristics

3. Antibody Drug Conjugates Market Trends And Strategies

4. Antibody Drug Conjugates Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Antibody Drug Conjugates Market Size and Growth

• 5.1. Global Antibody Drug Conjugates Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Antibody Drug Conjugates Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Antibody Drug Conjugates Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antibody Drug Conjugates Market Segmentation

• 6.1. Global Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monoclonal Antibodies
• Linker
• Drug/Toxin
• Other Types
• 6.2. Global Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Adcertis
• Kadcyla
• Other Products
• 6.3. Global Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Immunogen Technology
• Seattle Genetics Technology
• Immunomedics Technology
• Other Technology
• 6.4. Global Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Brain Tumor
• Other Applications
• 6.5. Global Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital
• Clinics
• Other End Users

7. Antibody Drug Conjugates Market Regional And Country Analysis

• 7.1. Global Antibody Drug Conjugates Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Antibody Drug Conjugates Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antibody Drug Conjugates Market

• 8.1. Asia-Pacific Antibody Drug Conjugates Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antibody Drug Conjugates Market

• 9.1. China Antibody Drug Conjugates Market Overview
• 9.2. China Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antibody Drug Conjugates Market

• 10.1. India Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antibody Drug Conjugates Market

• 11.1. Japan Antibody Drug Conjugates Market Overview
• 11.2. Japan Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antibody Drug Conjugates Market

• 12.1. Australia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antibody Drug Conjugates Market

• 13.1. Indonesia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antibody Drug Conjugates Market

• 14.1. South Korea Antibody Drug Conjugates Market Overview
• 14.2. South Korea Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antibody Drug Conjugates Market

• 15.1. Western Europe Antibody Drug Conjugates Market Overview
• 15.2. Western Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antibody Drug Conjugates Market

• 16.1. UK Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antibody Drug Conjugates Market

• 17.1. Germany Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antibody Drug Conjugates Market

• 18.1. France Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antibody Drug Conjugates Market

• 19.1. Italy Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antibody Drug Conjugates Market

• 20.1. Spain Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antibody Drug Conjugates Market

• 21.1. Eastern Europe Antibody Drug Conjugates Market Overview
• 21.2. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antibody Drug Conjugates Market

• 22.1. Russia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antibody Drug Conjugates Market

• 23.1. North America Antibody Drug Conjugates Market Overview
• 23.2. North America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antibody Drug Conjugates Market

• 24.1. USA Antibody Drug Conjugates Market Overview
• 24.2. USA Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antibody Drug Conjugates Market

• 25.1. Canada Antibody Drug Conjugates Market Overview
• 25.2. Canada Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antibody Drug Conjugates Market

• 26.1. South America Antibody Drug Conjugates Market Overview
• 26.2. South America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antibody Drug Conjugates Market

• 27.1. Brazil Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antibody Drug Conjugates Market

• 28.1. Middle East Antibody Drug Conjugates Market Overview
• 28.2. Middle East Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antibody Drug Conjugates Market

• 29.1. Africa Antibody Drug Conjugates Market Overview
• 29.2. Africa Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antibody Drug Conjugates Market Competitive Landscape And Company Profiles

• 30.1. Antibody Drug Conjugates Market Competitive Landscape
• 30.2. Antibody Drug Conjugates Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AbbVie Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AstraZeneca plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Antibody Drug Conjugates Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Millennium Pharmaceuticals Inc.
• 31.4. Gilead Sciences Inc.
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Daiichi Sankyo Company Limited
• 31.7. Sorrento Therapeutics Inc.
• 31.8. Astellas Pharma Inc.
• 31.9. Biogen Inc.
• 31.10. Zydus Lifesciences Limited
• 31.11. Seagen Inc.
• 31.12. Seagen Inc.
• 31.13. Progenics Pharmaceuticals Inc.
• 31.14. Synthon BV
• 31.15. Genentech Inc.

32. Global Antibody Drug Conjugates Market Competitive Benchmarking

33. Global Antibody Drug Conjugates Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antibody Drug Conjugates Market

35. Antibody Drug Conjugates Market Future Outlook and Potential Analysis

• 35.1 Antibody Drug Conjugates Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Antibody Drug Conjugates Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Antibody Drug Conjugates Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer